H

ello, everyone, and how are you today? Our morning is off to a fine start, thanks to a warm and shiny sun that is enveloping the Pharmalot campus, where the short person is sleeping in. A well-deserved respite from a taxing summer job. As for us, we are as busy as ever. It may be midsummer, but the world continues to spin. No doubt, you can relate. So here are some tidbits to help you along. Have a lovely day and do keep in touch …

The Food and Drug Administration is on pace to break its record for approving generic drugs, Regulatory Focus tells us. So far this fiscal year, the agency has approved 633 generics, which compares with a total of 651 approvals in fiscal year 2016, according to the latest activities report. And complete response letters, which signify rejections, are down significantly with 1,292 sent so far in fiscal year 2017, compared with 1,725 letters sent in fiscal year in 2016.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • With the generics business in a tailspin, in a year Teva can be scooped up by a branded company for pennies on the dollar. The Israeli government is well aware of this, which is why they are throwing a life preserver out to Teva. These promises between governments and pharma are worthless. Look at all the companies like Pfizer, that were lured by local governments to relocate in exchange for tax benefits. In the end Pfizer decided the quid wasn’t worth it and pulled up stakes.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy